MetaVia (NASDAQ:MTVA) Upgraded to Hold at Wall Street Zen

MetaVia (NASDAQ:MTVA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright dropped their price objective on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $26.50.

MetaVia Stock Down 7.6%

MetaVia stock opened at $1.22 on Friday. MetaVia has a 52-week low of $1.21 and a 52-week high of $23.10. The company has a market cap of $2.68 million, a P/E ratio of -0.15 and a beta of 0.33. The business has a 50-day simple moving average of $1.81 and a two-hundred day simple moving average of $6.80.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new position in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is owned by hedge funds and other institutional investors.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.